Featured Research

from universities, journals, and other organizations

Improved device provides more rapid, comprehensive analysis of circulating tumor cells

Date:
April 2, 2010
Source:
Massachusetts General Hospital
Summary:
Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment.

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment. A report from the Massachusetts General Hospital (MGH) Center for Engineering in Medicine in the March 31 Science Translational Medicine describes refinements to the MGH-developed CTC-chip, which measures levels of circulating tumor cells (CTCs) in the blood stream, that may allow better monitoring of how CTC levels react to treatment for prostate cancer and reveal key biological properties of the cells.

Related Articles


"The earlier versions of the CTC-chip required hand-counting of thousands of microscopic images, which was sufficient for the initial proof-of-principle studies but far too time-intensive for handling high volumes of patient samples," says Shannon Stott, PhD, of the MGH Center for Engineering in Medicine, the study's lead author. "We also were limited in our ability to analyze cellular factors that could be markers for important properties of the tumors."

CTCs are living solid-tumor cells found at extremely low levels in the bloodstream. Until the 2007 development of the CTC-chip by researchers from the MGH Cancer Center and Center for Engineering in Medicine, it was not possible to get information from CTCs that would be useful for clinical decision making. The updated system described in the current report incorporates improved imaging technology, allowing more complete visualization of cells captured by the device, and new software that automates the identification of CTCs using criteria specific to the particular type of tumor.

The MGH team used the automated system to analyze CTCs from two groups of prostate cancer patients. After the cells were initially captured on the CTC-chip, which is covered with microscopic posts coated with antibody to a common tumor protein, the cells were tagged using an antibody to prostate-specific antigen, allowing rapid scanning and more comprehensive visualization of the CTCs. Samples taken from a group of men with localized prostate cancer right before and at several intervals after surgical removal showed that, while CTCs disappeared immediately after surgery in some patients, CTC levels dropped only modestly in others. Analyzing CTCs from a group of patients being treated for metastatic prostate cancer revealed that, among patients whose tumors were responding to treatment, only a few CTCs displayed a marker found on proliferating cells. But in patients whose tumors were not responding, the majority of CTCs displayed the proliferation marker.

"Further studies are needed to determine whether the differences seen in our study actually reflect which tumors are more invasive, in the case of the persistance/disappearance observation, or reveal important biological properties of the tumor," says Stott, who is a research fellow in Surgery at Harvard Medical School. "We are also working to create a 'plug-and-play' version of the machine that will be easy to use clinically, exploring options for large-scale production of the CTC-chip, and continuing to optimize the device to increase its speed and efficiency."

Shyamala Maheswaran, PhD, of the MGH Cancer Center is senior author of the Science Translational Medicine report. Additional co-authors are Sunitha Nagrath, PhD, Alessandra Moore, Dina Tsukrov, and Mehmet Toner, PhD, MGH Center for Engineering in Medicine; Richard Lee, Min Yu, David Miyamoto, Lindsey Ulkus, Elizabeth Inserra, Matthew Ulman, Simeon Springer, Zev Nakamura, Maria Kempner, Chin-Lee Wu, Matthew Smith, MD, Lecia Sequist, MD, and Daniel Haber, MD, MGH Cancer Center; Douglas Dahl, MD, MGH Urology; John Iafrate, MD, PhD, MGH Pathology; and Ronald Tompkins, MD, ScD, MGH Surgery.

Funding for the research includes grants from Stand Up to Cancer; the Prostate Cancer Foundation; Howard Hughes Medical Institute; National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute; the American Cancer Society; the Ellison, Martell and Monell Foundations; AstraZeneca; and Alex and Sonja Spier.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "Improved device provides more rapid, comprehensive analysis of circulating tumor cells." ScienceDaily. ScienceDaily, 2 April 2010. <www.sciencedaily.com/releases/2010/03/100331141619.htm>.
Massachusetts General Hospital. (2010, April 2). Improved device provides more rapid, comprehensive analysis of circulating tumor cells. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/03/100331141619.htm
Massachusetts General Hospital. "Improved device provides more rapid, comprehensive analysis of circulating tumor cells." ScienceDaily. www.sciencedaily.com/releases/2010/03/100331141619.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins